<?xml version="1.0" encoding="UTF-8"?>
<document id="29263255">
	<sentence id="s1" text="Insertion of a single-chain variable-fragment antibody (scFv) to HER2 (human epidermal growth factor receptor 2) in gD, gH, or gB gives rise to herpes simplex viruses (HSVs) specifically retargeted to HER2-positive cancer cells, hence to highly specific nonattenuated oncolytic agents.">
		<entity id="s1.e1" charOffset="65-69"
			type="GENE" text="HER2" ontology_id="2064"/>
		<entity id="s1.e2" charOffset="215-221"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="true"/>
	</sentence>
	<sentence id="s2" text="Recently, we developed a double-retargeting strategy whereby gH carries the GCN4 peptide for retargeting to the noncancer producer Vero-GCN4R cell line and gD carries the scFv to HER2 for cancer retargeting.">
		<entity id="s2.e1" charOffset="115-121"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s2.e2" charOffset="179-183"
			type="GENE" text="HER2" ontology_id="2064"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="true"/>
	</sentence>
	<sentence id="s3" text="Here, we describe a double-retargeting strategy, based on the simultaneous insertion of two ligands in gD, one for retargeting to a producer, universal Vero cell derivative and one for retargeting to the HER2 cancer receptor.">
		<entity id="s3.e1" charOffset="204-208"
			type="GENE" text="HER2" ontology_id="2064"/>
		<entity id="s3.e2" charOffset="209-215"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="true"/>
	</sentence>
</document>
